Please login to the form below

Not currently logged in
Email:
Password:

Merck’s Michel Vounatsos moves to Biogen

He takes up the roles of executive vice president and chief commercial officer

Biogen has appointed Michel Vounatsos as its new executive vice president and chief commercial officer.

Vounatsos will begin at Biogen from 18 April with a remit to oversee the development and execution of the biotechnology firm's global commercial strategy, particularly focusing on the growth of its product portfolio and commercial infrastructure.

Dr George Scangos, Biogen's chief executive officer, said: “Michel is a sophisticated global business leader who brings a track record of commercial success and creativity to Biogen.

“As the complexity of our business and the expectations of our stakeholders accelerate, Michel will play a critical role in driving our near-term growth while helping prepare our organisation to support our increasingly robust and diverse pipeline.”

He brings 20 years of management experience at Merck, having first joined as director of marketing development of its New Jersey operations in 1996 and held increasingly senior roles in Europe and China until his most recent position as president, primary care and customer centricity in the US.

Vounatsos said: “I am excited to work with my new colleagues to deliver on the unique promise of the Biogen pipeline as we seek to transform the lives of patients with neurodegenerative and rare diseases around the world.

“As I move to Biogen, I am grateful to the team at Merck for the tremendous opportunities I have had over the past two decades.”

1st April 2016

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aurora Healthcare Communications

We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics